{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:39:25Z","timestamp":1764401965972,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vaccine.2022.06.084","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T22:56:34Z","timestamp":1662159394000},"page":"5835-5841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax\u00ae, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine"],"prefix":"10.1016","volume":"40","author":[{"given":"Xavier","family":"S\u00e1ez-Llorens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagros","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"DeAntonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens S\u00f8ndergaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena Messerschmidt","family":"Ekstrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela Katrine","family":"Czort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Henrik","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Thulstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorte Birk","family":"Christoffersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.06.084_b0005","unstructured":"Initiative GPE. Wild poliovirus list. https:\/\/polioeradication.org\/polio-today\/polio-now\/wild-poliovirus-list. Accessed 29 Oct 2021."},{"key":"10.1016\/j.vaccine.2022.06.084_b0010","unstructured":"Initiative GPE. Vaccine-Derived Polioviruses. https:\/\/polioeradication.org\/polio-today\/polio-prevention\/the-virus\/vaccine-derived-polio-viruses\/. Accessed 24 Feb 2022."},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.084_b0015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2022.06.084_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcdb.2020.12.008","article-title":"Aluminium adjuvants in vaccines \u2013 a way to modulate the immune response","volume":"115","author":"Danielsson","year":"2021","journal-title":"Semin Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.084_b0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1473-3099(17)30177-9","volume":"17","author":"Rivera","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.06.084_b0030","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.vaccine.2019.10.064","article-title":"Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14weeks and 9months of age","volume":"38","author":"Bravo","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.084_b0035","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2020.02.066","article-title":"Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15\u201318 months","volume":"38","author":"Saez-Llorens","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.084_b0040","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","article-title":"ethical principles for medical research involving human subjects","volume":"284","author":"World Medical Association Declaration of Helsinki","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.06.084_b0045","unstructured":"International Council of Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Integrated addendum to ICH E6(1): guideline for good clinical practice E6 (R2). 2016."},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.084_b0050","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.vaccine.2016.12.027","volume":"35","author":"Lindgren","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.084_b0055","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.06.084_b0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4049\/jimmunol.74.1.71","article-title":"The effect of gamma globulin on sub clinical infection in familial associates of poliomyelitis cases. II. Serological studies and virus isolations from pharyngeal secretions","volume":"74","author":"Brown","year":"1955","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2022.06.084_b0065","unstructured":"Robertson S. Module 6: Poliomyelitis. https:\/\/www.who.int\/ihr\/polio1993en.pdf. Accessed 03 Nov 2021."},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.084_b0070","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00431-014-2318-2","article-title":"How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study","volume":"173","author":"Bergfors","year":"2014","journal-title":"Eur J Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:44Z","timestamp":1759403744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22008581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":14,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0264410X22008581"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.084","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax\u00ae, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}